0000905718-20-001132.txt : 20201123 0000905718-20-001132.hdr.sgml : 20201123 20201123111444 ACCESSION NUMBER: 0000905718-20-001132 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201119 FILED AS OF DATE: 20201123 DATE AS OF CHANGE: 20201123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Winslow Garrett CENTRAL INDEX KEY: 0001803773 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37718 FILM NUMBER: 201335117 MAIL ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: C/O SPRING BANK PHARMACEUTICALS, INC. CITY: HOPKINTON STATE: MA ZIP: 01748 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: F-star Therapeutics, Inc. CENTRAL INDEX KEY: 0001566373 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522386345 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 44 1223 497400 MAIL ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: Spring Bank Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130108 4 1 springbank_fm4nov192020.xml X0306 4 2020-11-19 1 0001566373 F-star Therapeutics, Inc. SBPH 0001803773 Winslow Garrett C/O SPRING BANK PHARMACEUTICALS, INC. 35 PARKWOOD DRIVE, SUITE 210 HOPKINTON MA 01748 0 1 0 0 General Counsel and Secretary Common Stock 2020-11-19 4 M 0 6250 A 6250 D Common Stock 2020-11-19 4 A 0 12500 A 18750 D Common Stock 2020-11-20 4 S 0 175 4.76 D 18575 D Restricted Stock Units 2020-11-19 4 M 0 6250 0 D Common Stock 6250 0 D Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Exhibit 24: Power of attorney. On November 20, 2020, Spring Bank Pharmaceuticals, Inc. (the "Issuer") acquired the entire issued and outstanding share capital of F-star Therapeutics Limited pursuant to an exchange agreement. The combined company will operate under the name F-star Therapeutics, Inc ("F-Star"). All securities reported on this Form 4 reflect a one-for-four reverse stock split effective November 23, 2020. /s/ John Hogoboom, attorney-in-fact for Garrett Winslow 2020-11-23 EX-24 2 winslow_poa.htm POWER OF ATTORNEY

POWER OF ATTORNEY

Know all by these present that the undersigned hereby constitutes and appoints John Hogoboom as their true and lawful attorney-in-fact to:

execute for and on behalf of the undersigned Schedules 13D and 13G and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules thereunder;

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Schedules 13D or 13G, Form ID application for EDGAR codes, and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including, without limitation, the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedules 13D and 13G and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Exchange Act and the rules thereunder with respect to the undersigned's holdings of and transactions in securities issued by Spring Bank Pharmaceuticals, Inc. unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of November 16, 2020.

/s/ Garrett Winslow